- Home
- DAY vs ROIV Comparison
DAY vs ROIV Comparison
Compare DAY & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAY
- ROIV
- Stock Information
- Founded
- DAY 1992
- ROIV 2014
- Country
- DAY United States
- ROIV United Kingdom
- Employees
- DAY N/A
- ROIV N/A
- Industry
- DAY
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- DAY
- ROIV Health Care
- Exchange
- DAY NYSE
- ROIV Nasdaq
- Market Cap
- DAY 11.7B
- ROIV 8.4B
- IPO Year
- DAY 2018
- ROIV N/A
- Fundamental
- Price
- DAY $70.50
- ROIV $10.94
- Analyst Decision
- DAY Buy
- ROIV Strong Buy
- Analyst Count
- DAY 10
- ROIV 8
- Target Price
- DAY $81.40
- ROIV $17.93
- AVG Volume (30 Days)
- DAY 1.2M
- ROIV 5.3M
- Earning Date
- DAY 02-07-2025
- ROIV 02-11-2025
- Dividend Yield
- DAY N/A
- ROIV N/A
- EPS Growth
- DAY 1200.52
- ROIV N/A
- EPS
- DAY 0.34
- ROIV 5.89
- Revenue
- DAY $1,694,500,000.00
- ROIV $129,128,999.00
- Revenue This Year
- DAY $16.80
- ROIV $15.98
- Revenue Next Year
- DAY $12.22
- ROIV N/A
- P/E Ratio
- DAY $207.96
- ROIV $1.86
- Revenue Growth
- DAY 16.85
- ROIV 145.68
- 52 Week Low
- DAY $47.08
- ROIV $9.69
- 52 Week High
- DAY $82.69
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- DAY 36.78
- ROIV 38.75
- Support Level
- DAY $68.82
- ROIV $10.42
- Resistance Level
- DAY $74.66
- ROIV $11.82
- Average True Range (ATR)
- DAY 1.59
- ROIV 0.35
- MACD
- DAY -0.36
- ROIV -0.11
- Stochastic Oscillator
- DAY 28.47
- ROIV 29.21
About DAY DAYFORCE INC
Dayforce provides payroll and human capital management solutions targeting clients with 100-100,000 employees. Following the 2012 acquisition of Dayforce, Dayforce pivoted away from its legacy on-premises Bureau business to become a cloud HCM provider. As of fiscal 2022, about 80% of group revenue was derived from the flagship Dayforce platform geared toward enterprise clients. The remaining revenue is about evenly split between cloud platform Powerpay, targeting small businesses in Canada, and legacy Bureau products.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.